Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer (AFUGEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01964534
Recruitment Status : Unknown
Verified January 2017 by GERCOR - Multidisciplinary Oncology Cooperative Group.
Recruitment status was:  Active, not recruiting
First Posted : October 17, 2013
Last Update Posted : January 31, 2017
Celgene Corporation
Information provided by (Responsible Party):
GERCOR - Multidisciplinary Oncology Cooperative Group